Treatment of venous ulcers with pentoxifylline: a 6-month randomized, double-blind, placebo controlled trial.
The aim of this study was the evaluation of treatment with pentoxifylline in patients with venous ulcers in a 6-month, randomized, controlled trial. Treatment with placebo or pentoxifylline (PXF; 400 mg, 3 times daily) lasted 6 months and was associated to elastic bandaging. The endpoints were the number of limbs with complete healing and the variation in the area of ulceration. A group of 172 patients were included: 82 in the PXF group and 88 in the placebo group; 82 completed the study in the PXF group and 78 in the placebo group. Results. The two groups were comparable for age and sex distribution. The treatment was well tolerated. Complete healing was obtained in 67% of patients in the PXF group and 30.7% in the placebo group (p<0.02). The variations in the average area of ulceration were 86.7% (decrease) in the PXF group and 47% in the placebo group. The cost of treatment increased 21% with PXF but the cost due to non-healing of the ulcer was equivalent to a 44% increase (in comparison with the PXF group). In conclusion PXF is effective and cost-effective in improving ulcer healing in patients with chronic venous hypertension.
Belcaro
G
G
Department of Biomedical Sciences, Chieti University, Irvine2 Vascular Laboratory, Italy. cardres@pe.abol.it
Cesarone
M R
MR
Nicolaides
A N
AN
De Sanctis
M T
MT
Incandela
L
L
Geroulakos
G
G
D000368:Aged; D001458:Bandages / Q000191:economics; D003362:Cost-Benefit Analysis / Q000191:economics; D004311:Double-Blind Method; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010431:Pentoxifylline / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies; D013997:Time Factors; D014647:Varicose Ulcer / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D014665:Vasodilator Agents / Q000191:economics / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology
D014665:Vasodilator Agents; D010431:Pentoxifylline